This page is general information about how UK medicines law is structured. It is not legal advice, and it does not state what any reader may or may not lawfully do. Anyone with a question about their own position should put it to their own legal advisers or to their institution's compliance office.
One label, four separate matters
"Are peptides legal in the UK" is really several different matters wearing one label, and they have different answers. Whether a molecule may be researched, whether it may be supplied, whether it may be marketed as a medicine, and whether it may be given to a person are four separate matters governed by different provisions. A compound can sit comfortably on one side of one line and firmly on the wrong side of another.
"Peptide" is also not a legal category. UK law does not regulate peptides as a class in the way it regulates, say, controlled drugs. What it regulates is products — a medicinal product, a cosmetic product, a food supplement — and the classification follows from what a product is presented as and what it is intended to do, not from the chemistry of the molecule inside it. The same peptide can therefore appear in three different regulatory positions depending on the product it is part of.
What the MHRA regulates
The Medicines and Healthcare products Regulatory Agency regulates medicines for human use in the United Kingdom, principally under the Human Medicines Regulations 2012. The core mechanism is the marketing authorisation: a product may not generally be placed on the UK market as a medicine unless it holds one, and the authorisation attaches to a specific product with a specific composition for specific indications, not to an ingredient in the abstract.
Two consequences follow. A compound with no marketing authorisation cannot lawfully be marketed as a medicine in the UK — there is nothing to market it under. And a compound that does hold an authorisation somewhere in the world holds it for that product in that jurisdiction; the authorisation does not travel with the molecule. Tirzepatide, for instance, is the active ingredient of authorised medicines in several jurisdictions, and that authorisation says nothing whatever about research-grade tirzepatide supplied as a research material.
Whether a product falls inside the medicines framework at all turns substantially on presentation and intended purpose. A product presented as treating or preventing disease, or as having such an effect, is heading for classification as a medicinal product regardless of what its label says it is for. This is the reason research suppliers are so insistent about research-use-only wording: it is not decoration, it is the boundary.
Where research supply sits
Material supplied for in-vitro laboratory research is supplied outside the medicines framework. It is not authorised, and it is not required to be, because it is not being placed on the market as a medicine. That is the position every compound in this catalogue occupies.
Sitting outside the framework means going without everything the framework provides. There is no MHRA oversight of manufacture, no Qualified Person batch release, no pharmacopoeial monograph, no patient information leaflet and no pharmacovigilance route. A research supply chain is not a diminished version of a pharmacy supply chain; it is a different thing, and it should not be read as equivalent to one. That point is developed further in what research use only actually means.
Peptide Global is not a pharmacy and not a registered healthcare provider. It does not supply medicines, and it does not give medical or clinical advice. The questions it can answer concern specification, cold-chain handling, storage and dispatch.
Compounds with no UK authorisation
Several compounds in this catalogue are investigational: they hold no UK marketing authorisation and no licensed UK medicine contains them. Retatrutide is the clearest example, and the MHRA products register carries no entry for it — something any reader can confirm directly rather than take on trust. Cagrilintide is in a similar position.
Others are compounds whose sequences have been studied for decades without ever becoming UK medicines — BPC-157, TB-500, ipamorelin, Selank and Semax among them. Selank and Semax have a particular history here: both were developed in Russia and have been used clinically there, which is sometimes described loosely as their being "approved". Approval in one jurisdiction has no bearing on UK status, and neither holds a UK marketing authorisation.
Melanotan II deserves a specific mention because it is the compound in this catalogue the MHRA has commented on publicly, having warned against unlicensed tanning products containing it. That warning concerns products sold for use on people. It is one more reason the research-use-only basis of supply is not a formality.
What to ask instead
Because "is it legal" collapses several separate matters into one, it is more useful to take them one at a time. Is the compound authorised as a medicine in the UK — a matter of public record on the MHRA register. Is it being supplied, and accepted, on a research-use-only basis. Does the receiving institution's own policy permit holding it, which is frequently a stricter test than the law. And does an ethics committee or safety officer need to see it first.
The last two are the ones that actually stop work in practice, and they are decided inside the purchasing organisation rather than by any regulator. Purchasers are responsible for their own compliance with applicable law and with their institution's requirements, and nothing on this site substitutes for either.
Common questions
Is it legal to buy research peptides in the UK?
Research chemicals supplied for laboratory use sit outside the medicines framework rather than being prohibited by it, and are routinely supplied to and held by laboratories. That is a description of how the framework is structured, not a statement about any particular purchase — the answer for a specific compound, buyer and purpose depends on facts this page cannot know. Anyone who needs a definitive answer should take their own legal advice.
Do research peptides need MHRA approval?
No, because they are not being placed on the market as medicines. A marketing authorisation is what permits a product to be marketed as a medicine; material supplied for in-vitro research is not, so there is nothing for it to be authorised under. The absence of an authorisation is a consequence of the category, not a gap in it.
Does an approval in another country apply in the UK?
No. A marketing authorisation attaches to a specific product in a specific jurisdiction and does not travel with the molecule. A compound approved in the United States or in Russia holds no UK status by virtue of that approval, and research-grade material of the same compound holds none either way.
Can I import research peptides into the UK?
Importation raises customs and medicines questions that depend on the compound, the quantity, the declared purpose and the importer, and it is not something this page can answer. Peptide Global holds UK stock and dispatches from the United Kingdom, which removes the question for UK purchasers; details are on the shipping and delivery page.
Is Peptide Global a pharmacy?
No. Peptide Global is a supplier of research materials, not a pharmacy and not a registered healthcare provider. It does not supply medicines and does not give medical or clinical advice.
Products described in this guide
Supplied for laboratory research use only. UK delivery is free on every order, tracked as standard.
Continue reading
Research use only
Every compound named on this page is supplied by Peptide Global strictly for laboratory research use only. Nothing here is for human or veterinary use. These are not foods, supplements or cosmetics, and they are not intended to diagnose, treat, cure or prevent any disease. Nothing on this page is medical, veterinary or legal advice, and no part of it describes administration to a person or an animal.
Purchasers are responsible for their own compliance with applicable law and with the requirements of their institution or ethics committee. At checkout, purchasers confirm they are a qualified researcher aged 18 or over and that they accept the Research-Use-Only Policy and Terms & Conditions.
